Ganovo inhibits hepatitis C virus NS3/4A protease that is critical to HCV replication. In the phase III clinical trial conducted in Mainland China, Ganovo regimen (Ganovo in combination with PEGylated interferon and ribavirin) demonstrated a cure rate of 97% (SVR12) in genotype 1 non-cirrhotic patients, with a 12-week treatment duration.
Results from several earlier clinical trials conducted in Taiwan, USA, Europe, South Korea and Thailand show that Ganovo regimen demonstrated a cure rate of 91% and 100% in genotype 1 cirrhotic patients and genotype 4 non-cirrhotic patients, respectively.
Ascletis' mission is to address unmet medical needs in three therapeutic areas: anti-viral, cancer, and fatty liver disease, for the patients in China and worldwide.
With a fully integrated anti-viral platform covering the entire value chain from discovery and development to manufacturing and commercialization, the company is focusing on developing and commercializing innovative, best-in-class drugs against HCV, HIV and HBV.
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results